Newron reports investor group subscribes to 433,070 new shares for EUR 5.5 million in private placement

PUBT · 1d ago
Newron reports investor group subscribes to 433,070 new shares for EUR 5.5 million in private placement
  • Newron Pharmaceuticals priced a second tranche of its February 2026 financing, issuing 433,070 new shares for EUR 5.5 million.
  • Proceeds earmarked to fund the global ENIGMA-TRS Phase 3 evenamide program, extending cash runway beyond pivotal 12-week results.
  • The investor group previously committed up to EUR 38 million, including about EUR 15 million in an initial tranche at EUR 19.24 per share.
  • A third EUR 5.5 million tranche is expected by Nov. 30, 2026; a further EUR 12 million is conditional on positive Phase 3 results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newron Pharmaceuticals S.p.A. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2395220_en) on September 08, 2026, and is solely responsible for the information contained therein.